Frontiers in Immunology · 2022 · 31 citations · 44 references
MedicineImmunologyOncologyCancer ImmunologyCell TherapyImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyChimeric Antigen Receptor T-cell TherapyGlioblastomaImmune Checkpoint InhibitorsChimeric Antigen Receptor T Cell PharmacodynamicsDurable Clinical ResponseFlow Cytometry ImmunophenotypingGlioblastoma ImmunotherapyGlioblastoma Targeted TherapyImmune Checkpoint Inhibitor ResponseT-cell TherapyTherapeutic Target Validation
The epidermal growth factor receptor variant III (EGFRvIII) has been investigated as a therapeutic target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma. Earlier research demonstrated that phenotypic and genotypic characteristics in T cells and CAR T product predicted therapeutic success in hematologic malignancies, to date no determinants for clinical response in solid tumors have been identified. We analyzed apheresis and infusion products from the first-in-human trial of EGFRvIII-directed CAR T for recurrent glioblastoma (NCT02209376) by flow cytometry. Clinical response was quantified via engraftment in peripheral circulation and progression-free survival (PFS), as determined by the time from CAR T infusion to first radiographic evidence of progression. The CD4 + CAR T cell population in patient infusion products demonstrated PD1 expression which positively correlated with AUC engraftment and PFS. On immune checkpoint inhibitor analysis, CTLA-4, TIM3, and LAG3 did not exhibit significant associations with engraftment or PFS. The frequencies of PD1 + GZMB + and PD1 + HLA-DR + CAR T cells in the CD4 + infusion products were directly proportional to AUC and PFS. No significant associations were observed within the apheresis products. In summary, PD1 in CAR T infusion products predicted peripheral engraftment and PFS in recurrent glioblastoma.
44
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17
Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai et al. · Science Translational Medicine · 2017 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17